Inari Medical, Inc. Stock Price, News & Analysis

Inari Medical reported a strong second quarter in 2022, achieving $92.7 million in revenue, a 46% year-over-year increase. The company expanded its U.S. commercial footprint to over 270 territories and received FDA clearance for two new products. Gross profit stood at $82.4 million, resulting in an 88.8% gross margin. However, the operating expenses surged to $91.7 million, leading to a net loss of $10.2 million. Inari reaffirmed its full-year revenue guidance of $360 million to $370 million.

Inari Medical (NASDAQ: NARI) will announce its Q2 2022 financial results on August 3, 2022. A conference call is scheduled for 2:00 PM PT to discuss these results and recent highlights. The company specializes in medical devices for treating venous diseases, offering minimally invasive catheter-based solutions like the ClotTriever and FlowTriever systems, which are FDA-cleared and CE-marked for clot removal. Investors can join the conference call after registering.

Okami Medical Inc. has received FDA 510(k) clearance for its LOBO-7 and LOBO-9 Vascular Occluders, enhancing its LOBO portfolio designed for peripheral vascular interventions. These new devices, along with existing LOBO-3 and LOBO-5, enable efficient blood vessel occlusions, crucial for procedures requiring rapid response in trauma cases. According to the company's leadership, this expansion emphasizes their commitment to innovation in vascular embolization, potentially improving patient outcomes and procedural efficiency.

Inari Medical (NASDAQ: NARI) reported a strong first quarter for 2022, achieving revenue of $86.8 million, a 51% increase year-over-year. The company treated 8,800 patients, a sequential rise of 14%, and launched the new Intri24 device, enhancing its product line. Despite a net loss of $3.1 million, Inari revised its full-year revenue guidance upward to between $360 million and $370 million. The improved outlook reflects robust growth in U.S. operations and new product introductions.

Inari Medical, Inc. (NASDAQ: NARI) announced its management will present at the Bank of America 2022 Healthcare Conference on May 12, 2022, at 10:40 a.m. PT in Las Vegas. The presentation focuses on the company's innovative solutions for treating venous diseases, including FDA-cleared thrombectomy devices designed to remove large clots effectively. A live audio webcast of the event will be available on the company's website for 90 days under the 'Investor Relations' section.

Inari Medical, Inc. (NASDAQ: NARI) will release its Q1 2022 financial results on May 4, 2022. The company aims to transform the treatment of venous diseases with innovative catheter-based thrombectomy devices. Inari's ClotTriever is FDA 510(k)-cleared for deep vein thrombosis treatment, while FlowTriever is cleared for pulmonary embolism. Following the earnings release, a conference call will be held to discuss financial results and updates. Interested parties can access the live call and webinar via the company's investor relations website.

Inari Medical, Inc. (NASDAQ: NARI) announced the completion of a public offering, selling an additional 300,000 shares after exercising an over-allotment option. The total number of shares sold reached 2,300,000, generating approximately $186.3 million in gross proceeds at a price of $81.00 per share. Major underwriters included BofA Securities and Morgan Stanley. The transaction was conducted under an effective shelf registration statement filed with the SEC.

Inari Medical, Inc. (NASDAQ: NARI) has announced a public offering of 2,000,000 shares at $81.00 per share, expected to close around March 15, 2022. The underwriters have a 30-day option to purchase an additional 300,000 shares. Proceeds from this offering will support Inari’s mission to treat patients with venous diseases using their innovative catheter-based systems. The offering is registered under an effective shelf registration statement filed with the SEC.